To assess the rate of protocol-defined treatment failure and safety of lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r).
Design
Open-label, prospective, randomized (1:1), international multi-centre trial.
Methods
Adult HIV-1-infected patients were assigned LPV/r 400/100 mg twice daily or SAQ/r 1000/100 mg twice daily with two or more nucleoside reverse transcriptase inhibitors (NRTIs)/non-NRTIs. All patients, whether on or off the assigned treatment, were followed for 48 weeks.
Results
Of 339 randomized patients, 324 initiated assigned treatment (intention-to-treat/exposed [ITT/e] population). At 48 weeks, treatment failure occurred in 29/163 (18%) and 53/161 (33%) of patients in the LPV/r and SAQ/r arms, respectively (ITT/e, P=0.002, log rank test). In an analysis that also considered those patients who discontinued treatment as having failed treatment (ITT/e/discontinuation=failure), 40/161 (25%) LPV/r-treated individuals versus 63/161 (39%) SAQ/R-treated individuals failed treatment (P=0.005, log rank test). Discontinuation of the assigned treatment occurred in 23/163 (14%) patients in the LPV/r-treated group, compared with 48/161 (30%) in the SAQ/r-treated group (ITT/e; P=0.001). The primary reasons for premature discontinuation were non-fatal adverse events (LPV/r: 12/163; SAQ/r: 21/161) and patients’ choice (LPV/r: 7/163; SAQ/r: 8/161). In the on-treatment analysis of time to treatment failure, no difference was observed between the two arms (P=0.27, log rank test).
Conclusion
LPV/r had better antiretroviral effects compared with SAQ/r at the doses and in the formulations studied. This may have been a result of patients’ preferences and ability to adhere to assigned therapy, rather than a result of differences in the intrinsic potency of the study protease inhibitors.
References
1.
MoyleG.J., & BackD.Principles and practice of HIV-protease inhibitor pharmacoenhancement.HIV Medicine2001; 2: 105–113.
2.
BurgerD.M., HoetelmansR.M., HugenP.W., MulderJ.W., MeenhorstP.L., KoopmansP.P., BrinkmanK., KeuterM., DolmansW., & HeksterY.A.Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.Antiviral Therapy1998; 3: 215–220.
3.
DurantJ., ClevenberghP., GarraffoR., HalfonP., IcardS., Del GiudiceP., MontagneN., SchapiroJ.M., & DellamonicaP.Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study.AIDS2000; 14: 1333–1339.
4.
WalmsleyS., BernsteinB., KingM., ArribasJ., BeallG., RuaneP., JohnsonM., JohnsonD., LalondeR., JapourA., BrunS., & SunE.; M98-863 Study Team. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection.New England Journal of Medicine2002; 346: 2039–2046.
5.
MartinezE., DomingoP., GalindoM.J., MilinkovicA., ArroyoJ.A., BaldoviF., LarrousseM., LeonA., de LazzariE., & GatellJ.M.Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir–ritonavir.Clinical Infectious Diseases2004; 38: 1017–1023.
6.
Friis-MollerN., SabinC.A., WeberR., d'Arminio MonforteA., El-SadrW.M., ReissP., ThiebautR., MorfeldtL., De WitS., PradierC., CalvoG., LawM.G., KirkO., PhillipsA.N., & LundgrenJ.D.; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.New England Journal of Medicine2003; 349: 1993–2003.
7.
DragstedU.B., GerstoftJ., PedersenC., PetersB., DuranA., ObelN., CastagnaA., CahnP., ClumeckN., BruunJ.N., BenetucciJ., HillA., CassettiI., VernazzaP., YouleM., FoxZ., & LundgrenJ.D.; MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.The Journal of Infectious Diseases2003; 188: 635–642.
8.
KurowskiM., SternfeldT., HillA., & MoecklinghoffC.Comparative pharmacokinetics and short-term safety of twice daily (BID) fortovase/ritonavir and invirase/ritonavir, 9th Conference on Retroviruses and Opportunistic Infections 24–28 February 2002, Seattle, USA. Abstract 432-W.
9.
KirkO., PedersenC., LawM., GulickR.M., MoyleG., MontanerJ., EronJ.J.Jr., PhillipsA.N., & LundgrenJ.D.Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.Antiviral Therapy2002; 7: 271–281.
10.
Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products.CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN.Statistics in Medicine1995; 14: 1659–1682.
11.
PozniakA., GazzardB., AndersonJ., BabikerA., ChurchillD., CollinsS., FisherM., JohnsonM., KhooS., LeenC., LovedayC., MoyleG., NelsonM., PeterB., PhillipsA., PillayD., WilkinsE., WilliamsI., YuoleM.; BHIVA Writing Committee BHIVA Executive Committee. British HIV association (BHIVA) guidelines for the treatment of hiv-infected adults with antiretroviral therapy.HIV Medicine2003; 4 (Suppl 1): 1–41.
12.
LeeG.A., SeneviratneT., NoorM.A., LoJ.C., SchwarzJ.M., AweekaF.T., MulliganK., SchambelanM., & GrunfeldC.The metabolic effects of lopinavir/ritonavir in HIV-negative men.AIDS2004; 18: 641–649.
